NCT04294576 - Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

April 29, 2024

Study Completion Date

October 22, 2024

Conditions

Locally Advanced/Metastatic Solid Tumors

Interventions

DRUG

BJ-001

BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.

DRUG

Pembrolizumab

"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."

Trial Locations (5)

Mount Sinai, New York

Greenville Hospital System University Medical Center (ITOR), Greenville

Washington University School of Medicine, St Louis

NEXT Oncology, San Antonio

Northwest Medical Specialities, Tacoma